Clinical implications of cardiovascular outcome trials in type 2 diabetes

Herz
L G MellbinL Rydén

Abstract

Cardiovascular disease (CVD) is the main reason for premature death in patients with type 2 diabetes. Hyperglycemia, the hallmark of diabetes, has long been considered the link between diabetes and CVD, and many trials focused on preventing CVD manifestations by means of tight glucose control. However, diabetes is a multifactorial disease in which, e. g., insulin resistance, endothelial dysfunction, and factors such as hypertension and dyslipidemia contribute. Thus, treatment needs to be multifactorial and take cardiovascular aspects into account. Newer classes of drugs, originally launched for glucose lowering, among them dipeptidyl-peptidase (DPP)-4 inhibitors, sodium-glucose cotransporter (SGLT)-2 inhibitors, and glucagon-like peptide (GLP)-1 receptor agonists, have been studied in large cardiovascular outcome trials (CVOT). Several SGLT-2 inhibitors and GLP-1 receptor agonists are associated with a reduction of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke). Although the mechanisms behind the effects are not fully understood, an important reason for the benefits of SGLT-2 inhibitors seems be a reduction in heart failure, while GLP-1 receptor agonists may retard the developm...Continue Reading

References

Mar 6, 2002·Circulation·Peter LibbyAttilio Maseri
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
May 14, 2005·Diabetes Research and Clinical Practice·Milagros J JacobsNathan D Wong
May 12, 2007·International Journal of Clinical Practice·H E BaysUNKNOWN SHIELD Investigators' Group
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Aug 6, 2009·Diabetologia·UNKNOWN Control GroupM Woodward
Dec 20, 2011·Diabetes Care·Elizabeth R SeaquistUNKNOWN ACCORD Investigators
Jun 13, 2012·The New England Journal of Medicine·Hertzel C GersteinSalim Yusuf
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Sep 4, 2013·European Heart Journal·Linda G MellbinHertzel C Gerstein
Dec 4, 2014·The Lancet. Diabetes & Endocrinology·Anoop Dinesh ShahHarry Hemingway
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Feb 18, 2016·The New England Journal of Medicine·Walter N KernanUNKNOWN IRIS Trial Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 28, 2016·Cell Metabolism·Daniel J Drucker
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Apr 25, 2017·Diabetes Research and Clinical Practice·K OgurtsovaL E Makaroff
Jun 13, 2017·The New England Journal of Medicine·Steven P MarsoUNKNOWN DEVOTE Study Group
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Nov 13, 2018·JAMA : the Journal of the American Medical Association·Julio RosenstockUNKNOWN CARMELINA Investigators
Jan 1, 2019·Annals of Internal Medicine·Michael FralickElisabetta Patorno

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation
amputations

Software Mentioned

Clinical Disease Research Using Linked Bespoke Studies and Ele...
REG
CANVAS

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.